摘要
目的:同时检测癌基因EGFR、c-erbB-2、CD44v6和p53在大肠癌组织中的异常表达,分析不同表达水平患者组的3年生存率差异。方法:对63例存档大肠癌石蜡组织标本进行重新切片,分别采用EGFR、c-erbB-2、CD44v6和p53单克隆抗体进行免疫组化染色(SABC法)。所有病例均随访3年以上。结果:全部63例大肠癌中除4例(6.3%)无任何1种癌基因蛋白表达外,11例(17.5%)表达1种癌基因蛋白的患者3年生存率88.8%;19例(30.2%)表达2种癌基因蛋白的患者3年生存率70.5%;15例(23.8%)表达3种癌基因蛋白的患者3年生存率57.8%;14例(22.2%)表达全部4种癌基因蛋白的患者3年生存率22.2%,与前3组患者的3年生存率比较均有显著性差异(P<0.01)。结论:同时检测大肠癌组织4种癌基因蛋白异常表达可准确判断患者不良预后。
Objective:To investigate the3-year survival rate of colorectal cancers which have the co-expression of EGFR,c-erbB-2,CD 44 v6and p53proteins.Methods:Expressions of EGFR,cerbB-2,CD 44 v6and p53were detected with four monoclonal antibodies respectively by immunohistochemical SABC staining in63colorectal cancers.All the patients were followed up for42months.Results:Except 4(6.3%)patients with none of EGFR,c-erbB-2,CD 44 v6and p53expressions;the3-year survival rates of11(17.5%)patients with one expression,19(30.2%)patients with two expressions,15(23.8%)patients with three expressions and14(22.2%)patients with all four expressions were88.8%,70.5%,57.8%and22.2%respectively.The last rate was significantly lower than the former three rates(P<0.01).Conclusion:Detection of these four ex-pressions simultaneously may be helpful for assessing the patient with colorectal cancer being at greater risk of poor prognosis.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2002年第3期187-189,共3页
Chinese Journal of Clinical Oncology
